Ramelteon: a melatonin receptor agonist for the treatment of insomnia.
Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for the treatment of insomnia characterized by difficulty in sleep onset. It is a nonscheduled drug since it lacks the potential for abuse and does not interact with neurotransmitter receptors most associated with these phenomena. Although the effects of ramelteon use > 5 weeks are unknown, the available data confirms its safety and efficacy for short-term use. Clinical use and future research should uncover more information about ramelteon's properties.
Devi
V
V
Department of Pharmacology, Melaka Manipal Medical College, Manipal, India. vasudha_manipal@yahoo.co.in
Shankar
P K
PK
D004347:Drug Interactions; D006801:Humans; D007192:Indenes / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D044094:Receptors, Melatonin / Q000819:agonists*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D016896:Treatment Outcome
D007192:Indenes; D044094:Receptors, Melatonin; C495910:ramelteon